Prime Medicine Inc is a pioneering biotechnology firm based in Cambridge, Massachusetts, focused on advancing genetic therapies across a broad spectrum of diseases. Utilizing cutting-edge gene editing technology, Prime Medicine develops Prime Editors, innovative tools that enable precise DNA edits. These editors combine a Cas protein with a reverse transcriptase enzyme and a pegRNA for targeted action. The company is also exploring novel treatments for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome through a research partnership with Cimeio Therapeutics. Founded in 2019, Prime Medicine is at the forefront of genetic therapy innovation.
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part of investing is finding the right balance between risk and reward. As you…
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
